Patents by Inventor Adelbert Grossmann
Adelbert Grossmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140220633Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second cType: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
-
Publication number: 20140142283Abstract: The present invention relates to methods for obtaining a polypeptide in a monomeric form, the method comprising a) providing a solution containing the polypeptide in monomeric form and in aggregated form, wherein the ratio of monomeric to aggregated form is 4:1 or less, as determined by size exclusion chromatography, b) performing mixed-mode chromatography in bind-and-elute mode, or hydrophobic interaction chromatography in flow-through mode, or a size-exclusion chromatography, and c) performing a weak cation exchange chromatography in bind-and-elute mode or flow-through mode, and thereby obtaining the polypeptide in monomeric form.Type: ApplicationFiled: June 28, 2012Publication date: May 22, 2014Inventors: Monika Baehner, Adelbert Grossmann, Stefan Hepbildikler
-
Patent number: 8501439Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.Type: GrantFiled: April 22, 2010Date of Patent: August 6, 2013Assignee: Scil Proteins GmbHInventors: Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
-
Patent number: 8318671Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.Type: GrantFiled: October 11, 1999Date of Patent: November 27, 2012Assignee: Scil Proteins GmbHInventors: Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
-
Publication number: 20120214200Abstract: A pro-polypeptide which is useful for the expression of a polypeptide of interest in a prokaryotic cell. Therefore the pro-polypeptide is fused to the N-terminus of the polypeptide of interest. The pro-polypeptide as reported herein provides for improved expression yields and improves the handling of the fusion polypeptide (downstream processing, purification). For example, efficient endotoxin removal is effected while the protein of interest comprising the pro-polypeptide is bound e.g. to an affinity chromatography material. Thereafter the pro-polypeptide can efficiently be cleaved from the polypeptide of interest by the incorporated protease cleavage site with the cognate protease.Type: ApplicationFiled: August 25, 2011Publication date: August 23, 2012Inventors: Adelbert Grossmann, Friedrich Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20120190609Abstract: A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in ii) and thereby producing a lipid particle.Type: ApplicationFiled: August 25, 2011Publication date: July 26, 2012Inventors: Martin Bader, Monika Baehner, Adelbert Grossmann, Anton Jochner, Hubert Kettenberger, Silke Mohl
-
Publication number: 20110086026Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: July 26, 2010Publication date: April 14, 2011Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20110034672Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second cType: ApplicationFiled: January 15, 2009Publication date: February 10, 2011Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Greithanner, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
-
Patent number: 7807158Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.Type: GrantFiled: January 3, 2006Date of Patent: October 5, 2010Assignee: Roche Palo Alto LLCInventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20100203589Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.Type: ApplicationFiled: April 22, 2010Publication date: August 12, 2010Inventors: Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
-
Patent number: 7541163Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: August 14, 2007Date of Patent: June 2, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse
-
Publication number: 20080171363Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: August 14, 2007Publication date: July 17, 2008Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20080076710Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: May 4, 2007Publication date: March 27, 2008Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20080031853Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: August 15, 2007Publication date: February 7, 2008Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070225204Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 14, 2006Publication date: September 27, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070225205Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 14, 2006Publication date: September 27, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070025966Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: February 1, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070020734Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: January 25, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070020235Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: January 25, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20060263356Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: January 3, 2006Publication date: November 23, 2006Inventors: Josef Endl, Maria Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Regula, Ralf Schumacher, Stefan Seeber, Jan stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen